Nearly 80 percent of the state’s voters rejected the Drug Price Relief Act, which is designed to reduce prescription drug spending, according to the report. Under the ballot initiative, Ohio agencies, including the Medicaid department, would not be charged more for medicine than the U.S. Department of Veterans Affairs, the report states.
The vote followed an extensive campaign from both sides. Pharmaceutical industry-backed opponents to the ballot initiative argued most Ohioans could see drug prices rise if the measure passed due to the possible shift of drug costs from drug companies to Medicare patients and the privately insured, according to STAT. Supporters of the ballot initiative referenced rising drug prices and the relationship between the pharmaceutical industry and the opioid epidemic as part of their effort to garner “yes” votes.
In the end, the report states many voters said the messages from both sides left things unclear as far as the ballot initiative’s details and its potential impact.
More articles on supply chain:
Dr. Scott Gottlieb: FDA to accelerate approval for direct-to-consumer genetic tests
Surescripts partners with EHR vendors, PBMs to promote drug price transparency
2.3k Eli Lilly employees accept buyouts
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
